Key Capital Corporation (OTC: KCPC) partners and supports business initiatives with the potential to make a difference to our Health, Wealth, or Environment.
Following over 20 years of close association with Immunitor and witnessing the often unprecedented success of the clinical studies, I now look forward to the Key Capital partnering with Immunitor to bring their patented oral pill immunotherapeutics to the global market. The Immunitor licensing and partnering represents an extraordinary opportunity for Key Capital.
“The potential for progressing a class of oral pill immunotherapeutic disease treatment products that are safe and effective is exciting, however of more importance is getting these products approved and to the market.”
Jonathan Wong consults to Immunitor and formerly headed development of novel antimicrobial drugs against intracellular pathogens including pandemic viruses for the Canadian government at DRDC Suffield.